Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: CuttingEdge Bio who wrote (2822)	12/17/2019 12:34:54 AM
From: Miljenko Zuanic	1 Recommendation Recommended By CuttingEdge Bio Respond to of 3557

I think they had a choice between Evercore and P. Jaffray, they chose Jaffray who had rating...have no idea what is their rating on REGN. Schimmer seams not very friendly, regardless they have outperform rating before downgrade. Anyway, it is not that important. In next 2Q we will know where (near term) Eylea stand. Also, from high dose safety perspective, REGN (I guess) did accumulate data from 2mg Q2W Eylea dosing, which is actually 8mg Q8W,....so they are not entering new Eylea dose in BLIND fashion!